A vaccine company is a pharmaceutical or biotechnology firm whose core business is developing, manufacturing, and distributing vaccines that train the immune system to fight specific diseases. These companies range from global giants producing billions of doses a year to small biotech startups focused on a single experimental candidate. What makes them distinctive from other drug makers is the complexity and biological unpredictability of their products: a vaccine is not a simple chemical pill but a carefully engineered biological preparation that must provoke a precise immune response without causing the disease it aims to prevent. Understanding how these companies actually work means following a vaccine from its earliest molecular design through animal testing, large-scale manufacturing, regulatory clearance, global distribution, and ongoing safety monitoring after millions of people have already received it.
Identifying a Vaccine Target
Every vaccine starts with a question: which piece of the pathogen should the immune system learn to recognize? Vaccine companies invest heavily in computational and laboratory research to answer this. Scientists screen the proteins on a pathogen’s surface, looking for molecules that are exposed enough for the immune system to detect, stable enough to manufacture reliably, and distinct enough from human proteins that the vaccine won’t trigger the body to attack its own tissues. Computational tools can evaluate hundreds of candidate proteins at once, filtering them by characteristics like whether they sit on the pathogen’s outer membrane, whether they contain regions that immune cells can grab onto, and whether they share too much similarity with human proteins. That last filter matters because a vaccine target that resembles a human protein could, in theory, provoke an autoimmune reaction. Researchers typically exclude candidates that share more than about 30% identity with human proteins.1Scientific Reports. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches
This discovery phase can take years. For some diseases, the target is obvious: the spike protein on SARS-CoV-2 became the focus of COVID-19 vaccines almost immediately because researchers already knew related coronaviruses used similar proteins to enter human cells. For other pathogens, hundreds of candidates might need to be screened before a promising one emerges. A well-known cautionary example comes from early work on a meningitis B vaccine, where roughly 250 out of 600 candidate proteins failed during laboratory preparation because they contained structural features that made them difficult to produce reliably.1Scientific Reports. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches Failures like that are not setbacks in the dramatic sense; they are the normal, expected cost of narrowing down the right molecular target.
Preclinical Testing in Animals
Once a candidate target has been chosen and a prototype vaccine formulated around it, the next step is testing in animals. Mice are the most common starting point, followed by larger animals depending on the disease. Animal studies serve two purposes: they check whether the vaccine is safe enough to move forward, and they check whether it actually triggers the immune response researchers are hoping for. A vaccine that causes no harm but also produces no useful immunity is a dead end, just as one that provokes a strong response but also causes dangerous side effects would be.
Animal models are considered essential for this stage, but vaccine companies and regulators both understand their limits. The immune systems of mice, ferrets, and even non-human primates do not perfectly mirror the human immune system. Species-specific differences in how animals respond to antigens and adjuvants mean that a vaccine performing beautifully in mice can disappoint in human trials.2PubMed. Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans An added wrinkle is that most early vaccine work uses inbred mouse strains, which are genetically near-identical. This uniformity can mask problems that would surface later in genetically diverse human populations.2PubMed. Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans So while animal data is a required building block for any vaccine program, researchers treat it with considerable caution when projecting how well a vaccine will work in people.3PubMed Central. What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Consideration of Strategies to Improve the Value of Animal Models
Formulation and Delivery Systems
A vaccine is more than just the target antigen. How that antigen is packaged and delivered to immune cells matters enormously. If you inject a naked protein into someone’s arm, the body’s enzymes may chew it up before immune cells ever encounter it. Vaccine companies spend significant effort engineering delivery systems that protect the antigen, carry it to the right cells, and amplify the immune response.
Lipid-based delivery systems have become one of the most prominent approaches, especially after the success of mRNA COVID-19 vaccines. Tiny lipid nanoparticles wrap around the vaccine’s active ingredient, shielding it from degradation and helping it get taken up by the immune cells that need to process it.4PubMed Central. Emerging Trends in Lipid-Based Vaccine Delivery: A Special Focus on Developmental Strategies, Fabrication Methods, and Applications These nanoparticles can be engineered with specific surface charges, sizes, and compositions to fine-tune how the immune system responds. For example, positively charged lipid particles interact more readily with certain immune cells because those cells carry a negative surface charge, creating a natural electrostatic attraction that improves uptake.5Molecular Pharmaceutics. Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines
Beyond lipid nanoparticles, other delivery platforms include viral vectors (harmless viruses engineered to carry genetic instructions for the target antigen), protein subunits mixed with immune-boosting adjuvants, and inactivated or attenuated whole pathogens. Each platform has trade-offs in manufacturing complexity, storage requirements, and the type of immune response it produces. A vaccine company’s choice of platform shapes nearly every decision downstream, from how the product is made to how cold it needs to be kept during shipping.
Scaling Up Manufacturing
Making a few thousand doses for a clinical trial is a completely different challenge from making hundreds of millions of doses for a global rollout. The leap from laboratory bench to industrial production is one of the most technically demanding and expensive stages in a vaccine company’s work.
For vaccines grown in cell cultures, the process involves selecting the right host cells, cultivating them in bioreactors, infecting them with the vaccine virus or engineering them to produce the desired protein, and then purifying the product from a messy biological soup of cellular debris, DNA fragments, and unwanted proteins.6PubMed Central. Downstream processing of cell culture-derived virus particles Purification alone can involve multiple steps: enzymes to digest contaminating DNA, filters to remove particles, and membrane-based concentration methods to gather the vaccine product while washing away impurities.7PubMed Central. Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
Scaling up is not just about using bigger tanks. Conditions that work at the bench sometimes fail at industrial scale because fluid dynamics, nutrient distribution, and temperature control all behave differently in a 60-liter bioreactor than in a 3-liter flask. One study on an adenovirus-based tuberculosis vaccine candidate illustrated this well: researchers had to optimize growth media, develop a two-stage culturing strategy to maintain virus production at higher cell densities, and then validate that their purification process could remove more than 98% of unwanted cellular proteins while recovering over 60% of the vaccine particles.8PubMed. Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate Every percentage point of recovery matters when you’re trying to supply millions of doses.
mRNA vaccines introduce their own manufacturing puzzle. Rather than growing a virus, companies synthesize messenger RNA using enzymes and then wrap it in lipid nanoparticles. Researchers are even exploring microfluidic chip-based systems that could perform mRNA synthesis, purification, and encapsulation all on a single device, pointing toward a future where production could be more modular and decentralized.9PubMed Central. On-Chip De Novo Production of mRNA Vaccine in Lipid Nanoparticles
Quality Control and Batch Release
Before any batch of vaccine leaves the factory, it must pass a battery of quality checks. These tests assess whether the vaccine contains the right amount of active ingredient, whether it is pure enough, whether its structure is intact, and whether it still works biologically. A batch that looks fine chemically but fails to trigger the expected immune response in a lab assay won’t be released.
The specific tests depend on the type of vaccine. For protein-based vaccines, quality labs measure the protein content using spectrophotometric methods and check for aggregation that could affect both potency and safety. Immunological potency is typically gauged by measuring whether the vaccine triggers antibodies that bind to the correct target in standardized assays.10PubMed Central. Considerations for bioanalytical characterization and batch release of COVID-19 vaccines For mRNA vaccines, quality checks also include verifying the integrity and length of the mRNA strand and ensuring it is properly encapsulated in lipid nanoparticles. Each vaccine platform brings its own set of critical quality attributes, and the analytical methods must be tailored accordingly.11npj Vaccines. Considerations for bioanalytical characterization and batch release of COVID-19 vaccines
This is not just a formality. Vaccine companies operate under the principle that every dose in every vial in every batch should be essentially identical. Biological products are inherently more variable than chemical drugs, so achieving that consistency requires rigorous process control at every stage, from the raw materials entering the facility to the finished vials leaving it.
Clinical Trials and Regulatory Approval
Even after a vaccine has been shown to work in animals and can be manufactured at scale, it cannot reach the public until it completes human clinical trials and receives regulatory approval. Clinical trials typically proceed in three phases. Phase I enrolls a small group of volunteers, usually dozens, to confirm basic safety and the correct dosage. Phase II expands to hundreds or thousands of participants and begins measuring how well the vaccine triggers an immune response. Phase III is the large-scale test, enrolling thousands to tens of thousands of people to determine whether the vaccine actually prevents disease in real-world conditions.
Regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and their counterparts around the world review the trial data before granting approval. During the COVID-19 pandemic, regulators compressed their review timelines dramatically. In the United States, emergency use pathways cut what would normally be a review period of 40 to 70 days down to roughly 20 days, from initial submission to a final decision letter.12PubMed Central. Regulatory approval pathway for COVID-19 vaccine in USA, Europe and India That acceleration did not mean corners were cut on the data reviewed; it meant administrative steps were parallelized and priority was given to the COVID-19 submissions.
For a vaccine company, the regulatory phase is expensive and uncertain. Even a vaccine that looks promising in Phase II can fail in Phase III if the efficacy numbers don’t hold up in a larger, more diverse population. Companies often invest hundreds of millions of dollars before learning whether their product will ever reach market.
Cold Chain and Global Distribution
Vaccines are fragile biological products. Most must be kept refrigerated from the moment they are manufactured until the moment they are injected. This unbroken chain of temperature control, known as the cold chain, is one of the biggest logistical challenges in global health. If a shipment of vaccines sits too long at the wrong temperature, the product can lose potency and become useless.13PubMed. Accurate prediction of vaccine stability under real storage conditions and during temperature excursions
Different vaccines have different temperature requirements. Traditional vaccines generally need to be stored between 2°C and 8°C (roughly standard refrigerator temperature). Some mRNA vaccines initially required ultra-cold storage at around -70°C, which limited where they could be distributed, since most clinics and hospitals in lower-income countries lack that kind of freezer infrastructure. Vaccine companies have invested in reformulating their products for more forgiving storage conditions, and research into thermostable formulations continues to be a priority for reaching populations in tropical climates and remote areas.
Large vaccine companies often manage complex global supply chains that span dozens of countries. This includes not just temperature-controlled shipping but forecasting demand, managing inventory at regional distribution hubs, and coordinating with local health ministries. During pandemic conditions, these supply chains came under extraordinary strain.
Post-Market Safety Surveillance
A vaccine company’s responsibilities do not end once the product reaches arms. Clinical trials, even large ones, are inherently limited in size and follow-up time. A rare side effect that occurs in one out of every 100,000 recipients might not appear in a trial of 30,000 people. Post-market safety surveillance systems exist specifically to catch those signals after a vaccine is being used widely.14PubMed. A review of methodologic & data considerations for vaccine safety surveillance in the wake of the COVID-19 pandemic
In the United States, the Vaccine Adverse Event Reporting System (VAERS) is one of the most well-known passive surveillance tools. Anyone, whether a doctor, patient, or family member, can submit a report about a health event that occurred after vaccination. Researchers then analyze these reports using statistical methods to determine whether any particular event is being reported more often than expected by chance. For instance, a post-marketing study of RSV vaccines analyzed thousands of VAERS reports and identified dozens of safety signals that warranted closer clinical attention.15PubMed Central. Post-marketing safety monitoring of RSV vaccines: A real-world study based on the Vaccine Adverse Event Reporting System (VAERS) It is worth noting that a VAERS report does not prove the vaccine caused the event; it simply flags patterns worth investigating further. Active surveillance systems, which follow up with defined populations over time, provide stronger evidence about actual cause and effect.
Vaccine companies are required by regulators to participate in pharmacovigilance activities, including monitoring adverse events, submitting periodic safety update reports, and sometimes conducting additional post-approval studies. This ongoing monitoring is part of why vaccine safety can actually improve over time, as data from millions of real-world recipients adds resolution that no pre-approval trial could provide.
The Business of Vaccines
Vaccines have an unusual commercial profile. They are given to healthy people, often just once or a few times, rather than taken daily like many drugs. Historically, this made vaccines less attractive to pharmaceutical companies than chronic-disease medications, because the revenue per patient is lower. In recent decades, several factors have shifted this calculus: new higher-priced vaccines like those for HPV and shingles, the emergence of pandemic preparedness as a priority, and innovative financing mechanisms.
One such mechanism is the Advance Market Commitment (AMC), which aims to reduce the financial risk of developing vaccines for diseases that primarily affect lower-income countries. Vaccine companies may hesitate to invest in manufacturing capacity for a product when they’re uncertain whether countries can afford to buy it. The AMC model provides a legally binding commitment to purchase vaccines at a set price, giving manufacturers the confidence to scale up production. A pilot AMC for pneumococcal vaccines launched in 2009 to address exactly this problem, where perceived market risks were leading to underinvestment in vaccines that developing countries urgently needed.16PubMed Central. Advance market commitment for pneumococcal vaccines: putting theory into practice
Intellectual property adds another layer. Vaccine companies typically hold patents on their antigens, adjuvants, delivery systems, and manufacturing processes. These patents give them exclusive rights for a period of years, allowing them to recoup their development costs. But patent exclusivity also limits who else can make the vaccine, which can constrain supply in poorer countries. Proposals for technology and know-how banks have been floated as a way to transfer patented vaccine technologies to manufacturers in lower- and middle-income countries, potentially broadening global access without entirely eliminating the financial incentive to innovate.17PubMed Central. Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways
Supply Chain Vulnerabilities
The COVID-19 pandemic exposed how fragile vaccine supply chains can be, especially for newer platforms. mRNA vaccines depend on highly specialized raw materials, including plasmid DNA templates, modified nucleotides, enzymes used to transcribe the mRNA, and the lipid components of nanoparticles. A limited number of global suppliers produce these materials, which means a disruption at any one facility can ripple through the entire production chain.18PubMed Central. Unpacking the mRNA Supply Chain: Challenges and Opportunities for Global Health The stringent cold chain requirements for mRNA products add another layer of vulnerability, particularly for distribution to regions with limited infrastructure.
Traditional vaccine platforms face their own bottlenecks. Growing influenza vaccines in embryonated chicken eggs, for example, requires a massive and time-sensitive supply of fertilized eggs every season. Cell-culture-based and recombinant-protein platforms reduce dependence on eggs but introduce new dependencies on cell banks, growth media, and purification consumables. No vaccine platform is supply-chain-proof. The trend in the industry is toward diversifying suppliers and building regional manufacturing capacity to reduce the concentration risk that became painfully visible during the pandemic.
Updating Vaccines for Changing Pathogens
Some diseases do not sit still. Influenza is the textbook example: the virus mutates so rapidly that the vaccine must be reformulated every year. The World Health Organization convenes expert panels twice a year, once in February for the Northern Hemisphere and once in September for the Southern Hemisphere, to review global surveillance data and recommend which viral strains the next season’s vaccine should target.19PubMed. The annual production cycle for influenza vaccine Vaccine companies then race through two separate production campaigns each year to match these updated formulations, a cycle that repeats without pause.
COVID-19 vaccines have followed a loosely similar pattern, with updated boosters targeting new variants. The mRNA platform has a structural advantage here: because the manufacturing process synthesizes RNA from a digital genetic sequence, swapping in a new variant’s sequence is relatively fast compared to re-engineering a protein or growing a new virus strain. But even with that speed advantage, each updated formulation still needs to go through abbreviated regulatory review, quality testing, and manufacturing scale-up before it can reach clinics.
Vaccines Beyond Infectious Disease
The word “vaccine” still conjures images of childhood immunization schedules and flu shots, but vaccine companies are increasingly working on products that target non-infectious diseases. Cancer vaccines represent the most active frontier. Rather than preventing infection, these vaccines train the immune system to recognize and attack tumor cells. The most ambitious programs create personalized vaccines tailored to the unique set of mutations found in an individual patient’s tumor. These neoantigen vaccines analyze a biopsy, identify the abnormal proteins specific to that tumor, and manufacture a custom vaccine designed to provoke an immune response against those proteins.20PubMed Central / Elsevier. Personalized neoantigen cancer vaccines: An analysis of the clinical and commercial potential of ongoing development programs
The manufacturing and business model for personalized cancer vaccines looks nothing like traditional vaccine production. Instead of making millions of identical doses, a company produces a unique product for each patient, typically within weeks of receiving the biopsy. This requires flexible, rapid-turnaround manufacturing and a reimbursement model that can support per-patient pricing rather than per-dose bulk purchasing. Several biotech companies have programs in various stages of clinical development, and while the science is promising, the commercial viability of truly personalized vaccines at scale remains an open question that the industry is actively working to answer.